Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
Castle Biosciences will present late-breaking data on DecisionDx-Melanoma at the EADV 2026 Congress, from the largest prospective multicenter GEP study in cutaneous melanoma to date (2,799 patients across 29 U.S. centers). Low-risk i31-SLNB results showed observed SLN positivity of 4.4%, consistent with the test's <5% prediction, and 565 SLNB-eligible low-risk patients who skipped the procedure had five-year recurrence-free survival of 99.6%. A separate analysis of 687 transected melanomas showed the test stratified five-year RFS from 93.2% (Class 1A) to 64.1% (Class 2B), supporting risk-aligned surveillance when staging is uncertain.
Key figures
- Drug Name
- DecisionDx-Melanoma
- Test orders
- more than 240,000
- Study centers
- 29
- Study patients
- 2799
- Class 1a 5yr rfs
- 93.2%
- Class 2b 5yr rfs
- 64.1%
- Low risk sln positivity
- 4.4%
- High risk sln positivity
- 22.8%
- Low risk no slnb 5yr rfs
- 99.6%
- Peer reviewed publications
- 58
- Transected cohort patients
- 687
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.